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The Epstein-Barr virus (EBV) genome is highly methylated in latently infected cells. We recently reported
that the EBV immediate-early (IE) protein BZLF1 (Z) preferentially binds to and activates transcription from
the methylated form of the BRLF1 IE gene promoter (Rp). We now report that serine residue 186 in the Z
DNA-binding domain plays an important role in the ability of Z to bind to and activate methylated Rp. A Z
mutant containing an alanine residue at position 186 [Z(S186A)] was significantly defective in binding to
methylated, as well as unmethylated, ZREs (Z-responsive elements) in Rp and was unable to activate lytic EBV
gene transcription from the methylated or demethylated form of the viral genome. A Z mutant containing
threonine at residue 186 [Z(S186T)] bound only to the methylated form of the ZRE-2 site in Rp and induced
lytic EBV gene transcription from the methylated, but not demethylated, form of the viral genome. The defect
in both of these mutants was primarily due to an inability to activate the Rp in the context of the viral genome.
Finally, a Z mutant containing an aspartic acid at position 186 [Z(S186D)] did not bind to either the consensus
AP-1 site or to the methylated or unmethylated Rp ZRE-2 site and did not induce lytic gene transcription.
These results indicate that replacement of serine with threonine at residue 186 in the Z DNA-binding domain
differentially affects its ability to reactivate the unmethylated, versus methylated, viral genome.
Epstein-Barr virus (EBV) is the causative agent of infectious
mononucleosis and is associated with B-cell lymphomas, naso-
pharyngeal carcinoma, gastric carcinomas, and other malig-
nancies (44, 56). EBV primarily infects two cell types, epithe-
lial cells and B cells (44, 50). In normal oral epithelial cells, the
virus exists in a lytic state (34, 37, 44, 51), whereas EBV infec-
tion of B cells usually results in a latent type of infection (34,
44). However, in a small percentage of B cells, the virus peri-
odically reactivates and replicates in the lytic manner. This
reactivation is initiated by expression of the two immediate-
early genes, BZLF1 and BRLF1 (8, 13, 15, 33, 46, 47, 51, 55),
which encode the transcriptional activators Z and R, respec-
tively.
Z is a bZip protein homologous to the cellular proteins
c-Fos and c-Jun and binds directly to AP-1 and AP-1-like
motifs (known as Z-responsive elements [ZREs]) present in
many lytic viral promoters (12, 19, 21). Z expression results in
activation of lytic EBV gene expression in essentially all EBV-
positive cell lines. Z initially activates expression of the BRLF1
immediate-early promoter (Rp) by binding directly to three
somewhat atypical ZRE sites in Rp, referred to as ZRE-1,
ZRE-2, and the recently identified ZRE-3 (6, 41). Z and R
together then activate the expression of the entire complement
of lytic EBV genes, thus inducing lytic EBV infection.
The EBV genome in latently infected cells is extensively
methylated (18, 39). Methylation likely suppresses the expres-
sion of lytic viral genes, thus helping to maintain latent infec-
tion. In addition, methylation of viral promoters driving
LMP-1 and EBNA-2 expression is associated with the most
stringent form of viral latency (type I) (2, 18, 28, 30, 38, 52), in
which LMP-1 and EBNA-2 are not expressed. It has been
proposed that DNA methylation causes transcriptional repres-
sion by multiple different mechanisms, including modification
of the histone acetylation state and prevention of transcription
factor binding to DNA (5, 7, 9, 10, 14, 16, 26, 29, 31, 32, 35, 36,
40, 48, 49, 54). However, we have recently shown that Z un-
expectedly preferentially binds to and activates transcription
from the methylated form of Rp (6). In addition, Z preferen-
tially activates lytic EBV gene transcription from the methyl-
ated form of the viral genome in latently infected cells (6).
Two of the three known ZRE sites in Rp (ZRE-2 and
ZRE-3) contain CpG motifs and hence could be methylated in
latently infected cells. We recently showed that Z preferen-
tially binds to the methylated form of the Rp ZRE-2 site
(TGAGCGA) and binds only to the methylated form of the Rp
ZRE-3 site (TTCGCGA) (6). The Rp ZRE-1 site (TGAG
CCA) cannot be methylated. The crystal structure of a Fos-Jun
heterodimer bound to a consensus AP-1 site indicates that the
residues in the basic DNA-binding domain of c-Fos and c-Jun
which make direct contact with DNA are analogous to Z res-
idues 182, 185, 186, 189, and 190 and that Z residue 186 would
directly contact the methylated cytosine in the Rp ZRE-2 motif
(TGAGCGA) (25). Interestingly, the residues that directly
contact DNA are identical in the c-Fos, c-Jun, and Z proteins,
with the exception of the Z serine residue at position 186,
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which is an alanine at the analogous position in c-Fos and
c-Jun (23, 25).
A mutant Z protein in which serine 186 is switched to an
alanine, Z(S186A), efficiently activates promoters containing
the consensus AP-1 site in reporter gene assays. Nevertheless,
Z(S186A) cannot activate BRLF1 transcription from the viral
genome in latently infected cells (1, 23) and, hence, cannot
activate early gene transcription, which requires both the Z
and R proteins in the context of the intact viral genome.
Z(S186A) binds at least as well as wild-type Z to the consensus
AP-1 site but binds with reduced affinity in comparison to
wild-type Z to the unmethylated form of the Rp ZRE-2 site as
well as the Rp ZRE-1 site (1, 24). A mutant Z containing a
threonine at position 186, Z(S186T), was previously reported
to be only slightly reduced in comparison to wild-type Z in its
ability to activate BRLF1 transcription (as well as early gene
transcription) from the latent viral genome in Raji cells (24),
but its binding affinity to the Rp ZRE-1, ZRE-2, and ZRE-3
sites has not been previously reported.
In this paper, we have examined the effect of CpG methyl-
ation on Z(S186A) and Z(S186T) binding to the ZRE-2 and
ZRE-3 sites in Rp as well as the effect of viral genome meth-
ylation on the ability of these Z mutants to disrupt viral la-
tency. In addition, we have examined the phenotype of the
Z(S186D) mutant, which has not been previously described in
detail. We show that the Z(S186D) mutant does not bind to
either the consensus AP-1 site or the methylated or unmeth-
ylated forms of Rp ZRE-2 and cannot activate lytic gene tran-
scription. The Z(S186A) mutant, which binds as well as wild-
type Z to the AP-1 site, cannot bind efficiently to any of the
three Rp ZRE sites, regardless of their methylation status, and
cannot activate BRLF1 transcription (or early gene transcrip-
tion) from the intact viral genome in either the methylated or
unmethylated form. The Z(S186T) mutant, similar to wild-type
Z, binds only to the methylated form of the Rp ZRE-3 site.
Z(S186T) binds efficiently to the methylated form of the
ZRE-2 site, but in contrast to wild-type Z, has essentially lost
the ability to bind to the unmethylated form of ZRE-2. Con-
sistent with this DNA-binding profile, the Z(S186T) mutant
can activate BRLF1 as well as early gene transcription from the
methylated but not unmethylated form of the viral genome.
These results indicate that residue 186 in the Z DNA-binding
domain plays a critical role in regulating the affinity of Z
binding to methylated as well as unmethylated Rp ZRE sites.
MATERIALS AND METHODS
Cell lines. The 293/EBV-ZKO cell line was derived by infecting human em-
bryonic kidney 293 cells with a BZLF1-deleted (green fluorescent protein [GFP]-
containing) EBV genome as previously described (20). 293T is a derivative of the
293 cell line which expresses the simian virus 40 (SV40) large T antigen. DG75
is an EBV-negative Burkitt’s lymphoma cell line. The AGS-EBV cell line was
derived by infecting the AGS gastric carcinoma line with wild-type (GFP-con-
taining) B95-8 virus. The GFP gene was inserted into the wild-type and BZLF1-
deleted versions of the B95-8 genome at the site of the right hand (dispensable)
copy of oriLyt as previously described (20). D98/HE-R1 cells are a fusion line
created with HeLa cells and the Burkitt lymphoma P3HR1 line. LCL-1 is a
lymphoblastoid cell line derived using wild-type (GFP-containing) B95-8 virus.
Raji is an EBV-positive Burkitt lymphoma line.
Plasmids. Plasmid DNA was purified through QIAGEN columns as described
by the manufacturer. Rp-CAT contains the immediate-early BRLF1 promoter
sequences from 962 to 5 linked to the chloramphenicol acetyltransferase
(CAT) gene. The Z expression vector (pSG5-Z) contains genomic Z downstream
of the SV40 promoter (a gift from S. Diane Hayward) in the pSG5 vector
(Stratagene). The Z(S186A) expression vector (a gift from Erik Flemington)
contains a point mutation at Z residue 186 which converts serine to alanine; the
Z(S186T) expression vector (a gift from George Miller) contains a point muta-
tion at amino acid 186 which converts serine to threonine. The Z cDNA (a gift
From Paul Farrell) was cloned into the SG5 vector to create SG5-ZcDNA. This
vector was used to in vitro translate the Z protein. Z(S186A) and Z(S186T)
mutations in the SG5-ZcDNA vector were constructed using the QuikChange
site-directed mutagenesis kit (Stratagene) to allow in vitro translation of the
mutant proteins. A Z(S186D) mutant was also constructed in the context of the
SG5-ZcDNA vector and used to in vitro translate this mutant as well as express
it in transfected cells. The R expression plasmid contains genomic R sequences
downstream of the SV40 promoter in the pSG5 vector (a gift from S. Diane
Hayward). The GST-Z vector was constructed as previously described (43) and
contains the BZLF1 protein fused in frame to the glutathione S-transferase
(GST) protein.
Determining the methylation status of the Epstein-Barr virus BRLF1 pro-
moter. Total genomic DNA was isolated from cultured EBV-positive cells using
the DNeasy tissue kit (QIAGEN). Bisulfite modification of genomic DNA was
performed as previously described (27). Briefly, 1 g of genomic DNA was
denatured by the addition of 5 l 2 N NaOH followed by incubation at 37°C for
10 min. Modification of C residues was accomplished by the addition of 30 l of
10 mM hydroquinone (Sigma) and 520 l of 3 M sodium bisulfite, pH 5.0
(Aldrich), followed by incubation at 50°C for 16 h. Modified DNA was purified
using a Wizard DNA cleanup kit (Promega) and eluted from the resin with 50 l
H2O preheated to 70°C. The final desulfonation was accomplished by the addi-
tion of 2 N NaOH to 0.3 N (8.9 l) followed by incubation at room temperature
for 5 min. The DNA was ethanol precipitated, and the final pellet was resus-
pended in water. Bisulfite-modified EBV genomic DNA was amplified using Taq
polymerase (Promega) in 1 buffer, 1.5 mM MgCl2, 0.2 mM concentrations of
deoxynucleoside triphosphates, and 10 pmol of each primer. Primary PCR was
performed using the EBV R promoter primers 5-TGTGTAGTGAGGTGTTG
TGTTTTG-3 and 5-TTTTAACTACAATATTTCCTCCAAAAA-3. Nested
PCR was performed using the primers 5-TGTGTAGTGAGGTGTTGTGTTT
TG-3 and 5-TGAGGTGTTGTGTTTTGTATGGT-3. Thermal cycler condi-
tions for the primary and nested PCR were as follows: 1 cycle at 94°C for 2 min
followed by 35 cycles of 94°C for 30 seconds, 58°C for 30 seconds, 72°C for 30
seconds, and a final cycle of 72°C for 7 min. PCR products were agarose gel
purified with a QIAGEN gel extraction kit and then cloned into the pCR
2.1-TOPO vector (TOPO TA cloning kit; Invitrogen) according to the manufac-
turer’s instructions. For each cell line, 10 clones were sequenced using ABI prism
(UNC-CH Automated DNA Sequencing Facility) to determine the methylation
status of the BRLF1 promoter.
Probes for EMSA. The oligonucleotides listed below were synthesized with or
without methylated cytosines at the CpG motif(s) within potential ZRE sites
(MWG Biotech and Oligos, Etc., Inc.). The sequences of the oligonucleotides
used in electrophoretic mobility shift assays (EMSAs) are shown below. Positions
of the oligonucleotides in the EBV genome relative to the BRLF1 start site are
shown in parentheses. ZRE sequences are underlined. The oligonucleotides
were either unmethylated or methylated at the cytosine shown in boldface type.
Synthetic oligonucleotides containing the Rp ZRE-1 site, or the AP-1 site in the
BMRF1 promoter, were made as previously described (1). Synthetic double-
stranded oligonucleotides were 5 end labeled with 32P using the Klenow reac-
tion. The oligonucleotides and sequences are as follows: ZRE-2 (184 to 203),
5-GATCAAGCTTATGAGCGATTTTAT-3 and 5-GATCATAAAATCGCT
CATAAGCTT-3; ZRE-3 (245 to 264), 5-GATCTCAAAATTCGCGATG
CTATA-3 and 5-GATCTATAGCATCGCGAATTTTGA-3.
EMSA. Labeled probes were incubated either with in vitro-translated wild-
type Z, Z(S186A), or Z(S186T) from reticulocyte lysate (or the untranslated
lysate) or whole-cell extracts made from DG75 cells electroporated with either
the empty pSG5 vector or plasmid expressing wild-type Z, Z(S186A), Z(S186T),
or Z(S186D). In vitro-translated wild-type and mutant Z proteins were made
using the TNT T7 quick-coupled transcription/translation system (Promega)
according to the manufacturer’s instructions. DG75 extracts were made 48 h
after transfection by suspending the cells in 200 l of a buffer containing 50 mM
HEPES (pH 7), 250 mM NaCl, 0.1% NP-40, 5 mM EDTA, 5 mM dithiothreitol,
1 Complete protease inhibitors (Roche), and 15% glycerol, followed by freeze-
thawing twice and centrifugation. The supernatant was used for EMSAs. Z
binding reactions were performed in a buffer consisting of 100 mM KCl, 20 mM
HEPES (pH 7.3), 10% glycerol, 0.2 mM EDTA, and 4 mM dithiothreitol with 2
g of poly(dI-dC)/poly(dI-dC) (Pharmacia). Bovine serum albumin (10 g; Pro-
mega) was added to EMSA mixtures with purified GST-Z. Five micrograms of
DG75 whole-cell extracts or 2 l of in vitro-translated protein was added to each
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reaction mixture and incubated at 4°C for 10 min before the addition of labeled
probe (10,000 cpm). For competition EMSAs, a 10-fold, 50-fold, or 250-fold
excess of cold competitor DNA was also added to the reaction mixture prior to
the addition of labeled probe. The reaction mixtures were incubated further for
30 min at 4°C after the addition of labeled probe. The reaction mixtures were
then loaded onto a 4% polyacrylamide gel and run in 0.5 Tris-borate-EDTA
buffer at room temperature. The binding was quantitated using a phosphorim-
ager (Molecular Dynamics) or NIH Image (National Institutes of Health).
Expression and purification of GST-Z protein. Saturated bacterial culture
(250 l) was diluted in 10 ml of LB plus ampicillin and incubated at 37°C to an
A600 of 0.6. Protein expression was induced with 1 mM isopropyl--D-thiogalac-
topyranoside (IPTG) and incubation at 30°C for 2 h. Bacteria were pelleted,
resuspended in 500 l of 1 phosphate-buffered saline (PBS), and then soni-
cated on ice. Fifty microliters of 1 PBS plus 10% Triton X-100 was added, and
the mixture was then centrifuged for 10 min at 13,000 rpm at 4°C. A mixture of
100 l of extract, 50 l of 50% slurry of glutathione-agarose beads, and 500 l
of buffer C (50 mM Tris [pH 7.5], 100 mM NaCl, 5 mM MgCl2, 0.1% NP-40, 10%
glycerol, 1 Complete protease inhibitors [Roche]) was incubated at 4°C for 2 h
on an orbital mixer (Adams Nutator). Beads were pelleted, and the supernatant
was removed, resuspended in 500 l of buffer C, and then incubated for 5 min at
4°C on a nutator. Beads were repelleted and washed three times with buffer C.
The bead pellet was then resuspended in 100 l of 50 mM Tris (pH 7.5) and 20
mM reduced glutathione and incubated on a nutator for 5 min at room temper-
ature. Beads were pelleted for 1 min at 13,000 rpm, and the supernatant was
removed to a microcentrifuge tube. This step was repeated. The combined
supernatant was dialyzed with a 3,500-molecular weight cutoff Slide-A-Lyzor
mini dialysis unit (Pierce) against 50 mM Tris (pH 8.0) and 10% glycerol for 2 h
at 4°C.
CAT assays. CAT vectors were mock methylated or methylated in vitro using
SssI CpG methylase (New England Biolabs), and methylation was confirmed by
complete resistance to HpaII cutting. Methylated plasmids were subsequently
cleaned by phenol-chloroform extraction and ethanol precipitation prior to
transfection into cells. Cell extracts were prepared 2 days posttransfection and
incubated at 37°C with [14C]chloramphenicol in the presence of acetyl coenzyme
A. The percent acetylation was determined by thin-layer chromatography fol-
lowed by phosphorimager screening (Molecular Dynamics).
DNA transfection. DNA (1 g of the CAT construct plasmids and 4 g of the
protein expression plasmids) was transfected into DG75 cells resuspended in
RPMI 1640 medium (Gibco BRL) by electroporation with a Zapper electropo-
ration unit (Medical Electronics Shop, University of Wisconsin) at 1,500 V.
Lipofectamine 2000 (Gibco BRL) was used to transfect DNA into EBV-positive
293 cells (or 293T cells) according to the manufacturer’s instructions. A DNA/
Lipofectamine 2000 ratio of 1:2 (mass/volume) was used.
Viral genome methylation influence on disruption of viral latency. 293 cells
latently infected with a Z-deleted EBV genome (293/EBV-ZKO) were treated
for 5 days in the presence or absence of 5-aza-2-deoxycytidine (5-aza-2-dc, 1
M; Sigma). 5-Aza-2-dc was removed during the lipofection procedure and then
replaced after 6 h. Expression of lytic EBV proteins was quantitated by immu-
noblot analysis 2 days after transfection.
Immunoblot analysis. Cell extracts harvested as described for the CAT assays
or cell extracts made using a buffer containing 150 mM sodium chloride, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM
Tris (pH 8.0), 50 mM sodium fluoride, 50 mM -glycerophosphate, 2 mM
sodium vanadate, and 1 Complete protease inhibitor (Roche) were electro-
phoresed on a 7% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
denaturing gel. The proteins were transferred onto a nitrocellulose membrane
(Protran), blocked in 1 PBS–5% milk–0.1% Tween 20, and incubated with
primary antibody for 1 h at room temperature using anti-EBV BZLF1 (Z, 1:100;
Argene), anti-BRLF1 (R, 1:100; Argene), anti-EBV EA-D (BMRF1, 1:100;
Capricorn), or anti--actin (1:5,000; Sigma) antibody. The membrane was
washed with 1 PBS–0.1% Tween 20, incubated with secondary antibody (goat
anti-mouse -horseradish peroxidase, 1:10,000; Southern Biotechnology) at
room temperature for 1 h, and washed. The results were visualized with the ECL
chemiluminescent kit (Amersham) according to the manufacturer’s instructions.
RESULTS
The BRLF1 promoter is highly methylated in cells with
latent EBV infection. To determine the extent of BRLF1 pro-
moter (Rp) methylation in latently infected cells, we examined
its methylation status in five different EBV-infected cell lines
using sodium bisulfite/PCR analysis. The cell lines examined
included two epithelial cell lines (EBV-positive gastric carci-
noma [AGS] cells and EBV-positive 293 cells), a fusion line
created with HeLa cells and the Burkitt lymphoma P3HR1 line
(D98/HE-R1 cells), a lymphoblastoid cell line (LCL-1), and a
Burkitt lymphoma line (Raji). Following bisulfite treatment of
the DNA, the BRLF1 promoter sequence was cloned and 10
independent clones were sequenced for each cell line.
The Rp sequence was highly methylated in each of the cell
lines analyzed, whether epithelial or B-cell derived (Fig. 1).
The CpG motif contained within the Rp ZRE-2 site (TGAG
FIG. 1. The BRLF1 IE promoter (Rp) is highly methylated in latently infected cells. The methylation status of CpG sites in Rp in 5
EBV-positive cell lines (indicated on the left) was determined by sodium bisulfite treatment followed by PCR and sequencing. The position of each
CpG site, represented by a diamond, with respect to the R transcription start site (1) is indicated at the top. The percentage of clones with meth-
ylated CpG at each position is indicated on top of the diamond representing that CpG for each cell line analyzed; 10 clones for each cell were sequenced.
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CGA) was almost completely methylated in every cell line
examined, with the exception of the AGS-EBV cells, in which
this site was methylated in 60% of the clones sequenced. In-
terestingly, the AGS-EBV cells have a small amount of detect-
able constitutive BRLF1 gene expression, whereas the other
cell lines are essentially completely latent (data not shown),
suggesting that activation of Rp by cellular transcription fac-
tors may preferentially occur when the promoter is less meth-
ylated. The methylation status of the Rp ZRE-3 site was also
examined in EBV-positive 293 cells; the ZRE-3 site was fully
methylated in this cell line (data not shown). As Z efficiently
induces BRLF1 expression in 293 cells (as well as the other
lines examined), these results indicate that Z activates BRLF1
transcription in latently infected cells even when the Rp
ZRE-2 and ZRE-3 sites are methylated.
Z residue 186 regulates binding to the methylated and un-
methylated forms of the Rp ZREs. We recently showed that
wild-type Z preferentially binds to and activates transcription
from the methylated form of Rp (6). To determine whether Z
residue 186 regulates binding to methylated ZRE sites, we
performed EMSAs to compare the ability of in vitro-translated
wild-type Z, Z(S186A), and Z(S186T) to bind to labeled oli-
gonucleotide probes containing the ZRE-1, ZRE-2, or ZRE-3
sites in Rp or the consensus AP-1 site from the BMRF1 early
viral promoter. The ZRE-2 and ZRE-3 probes were synthe-
sized so that they contained either unmethylated or methylated
cytosine at the CpG motifs.
The in vitro-translated Z(S186A) mutant was impaired in
comparison to wild-type Z for binding to the ZRE-1 site (Fig.
2A), the unmethylated as well as methylated forms of the
ZRE-2 site (Fig. 2A), and the methylated ZRE-3 site (Fig. 2B),
although as previously reported (1, 24), it bound at least as well
as wild-type Z to the consensus AP-1 site (Fig. 2B). The in
vitro-translated Z(S186T) mutant was partially compromised
for binding to the Rp ZRE-1 site (Fig. 2A), the consen-
sus AP-1 site (Fig. 2B), and the methylated Rp ZRE-3 site
(Fig. 2B). Most interestingly, however, while binding of the
Z(S186T) mutant to the unmethylated form of the Rp ZRE-2
site was severely impaired (only 2% binding compared to the
wild-type protein), it bound almost as well as the wild-type Z to
the methylated form of Rp ZRE-2 (Fig. 2A). Competition
analysis using the methylated versus unmethylated forms of
ZRE-2 as cold competitor DNA confirmed that the Z(S186T)
mutant bound almost exclusively to the methylated form of
ZRE-2 (Fig. 3). These results indicate that Z residue 186
regulates binding to both methylated and unmethylated ZRE
sites in the BRLF1 promoter.
EMSA was also performed using whole-cell extracts of
DG75 cells transfected with expression vectors for wild-type
Z, Z(S186A), or Z(S186T) (Fig. 4A). When transfected into
DG75 cells, the Z(S186A) mutant was even more impaired in
its binding (relative to wild-type Z) than when expressed as an
in vitro-translated protein. In DG75 cells, Z(S186A) bound
extremely poorly to the unmethylated and methylated forms
of all three Rp ZRE sites (Fig. 4A), although binding to the
AP-1 site was observed (data not shown). In the case of the
Z(S186T) mutant, although its expression level was much
higher than wild-type Z in DG75 cells (Fig. 4B), Z(S186T)
binding to the unmethylated form of ZRE-2 was almost unde-
tectable, while this mutant clearly bound to the methylated
FIG. 2. Mutation of Z residue 186 affects binding to the three Rp
ZRE sites. Binding of in vitro-translated wild-type Z (Wt Z), Z(S186A),
and Z(S186T) to oligonucleotide probes containing the Rp ZRE-1 or
ZRE-2 sites (A) or the Rp ZRE-3 site or the AP-1 site in the early EBV
BMRF1 gene promoter (BMRF1-AP-1) (B) was compared. The se-
quences and methylation status of each probe are indicated. Rabbit
reticulocyte lysate (retic) was used as a negative control for each probe.
The binding abilities of mutant Z proteins to each probe were measured
relative to wild-type Z, which was set at 100% for each probe. ND,
nondetectable binding; , present; , absent. (C) The expression level
of each in vitro-translated Z protein was analyzed by immunoblotting.
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form of this site (Fig. 4A). When the expression levels of wild-
type Z and Z(S186T) in DG75 cells were normalized, the two
proteins bound to methylated Rp ZRE-2 with similar efficiency
(Fig. 4C). The partial defects of in vitro-translated Z(S186T)
binding to the ZRE-1 (Fig. 2A) and ZRE-3 (Fig. 2B) sites were
not apparent when this mutant was expressed in DG75 cells at
a high level (Fig. 4A).
Z residue 186 plays a critical role in activating methylated
Rp. To determine whether Z serine residue 186 is required for
activation of methylated Rp, we compared the ability of wild-
type Z, the Z(S186A) mutant, and the Z(S186T) mutant to
activate the methylated or unmethylated Rp-CAT construct in
DG75 (Fig. 5A) or 293T (Fig. 5B) cells. Prior to transfection,
the CAT vectors were methylated (or mock methylated) with
SssI. Methylation was confirmed by resistance to HpaII cutting
(data not shown). The mock-methylated or methylated Rp-
CAT construct was cotransfected with a control vector or vec-
tors expressing either wild-type Z or one of the Z mutants.
We have previously shown that all three Rp ZRE sites are
important for activation of the unmethylated BRLF1 promoter
by wild-type Z, whereas only the ZRE-2 and ZRE-3 sites
(which can be methylated) are required for activation of the
methylated promoter (6). Consistent with its inability to bind
to either the methylated ZRE-2 site or the methylated ZRE-3
site in vivo (Fig. 4A), the Z(S186A) mutant was unable to
activate the methylated form of Rp-CAT in either DG75 cells
(Fig. 5A) or 293T cells (Fig. 5B). Somewhat surprisingly, given
its poor binding in vivo to each of the unmethylated Rp ZRE
sites (Fig. 4A), the Z(S186A) mutant could activate the un-
methylated form of Rp-CAT in DG75 cells (Fig. 5A). This
result suggests that Z(S186A) may activate the unmethyl-
ated BRLF1 promoter in plasmid-based reporter gene assays
through a mechanism not involving direct DNA binding.
The Z(S186T) mutant, which binds to the methylated but
not unmethylated form of ZRE-2 and is partially defective for
binding to the ZRE-1 and ZRE-3 sites, was defective for ac-
tivation of the unmethylated form of Rp-CAT (in DG75 cells)
(Fig. 5A) and partially defective for activation of the methyl-
ated form of Rp-CAT in DG75 (Fig. 5A) and 293T cells (Fig.
5B). These results suggest that Z residue 186 is important for
activating methylated Rp in vivo.
Z residue 186 regulates the ability of Z to induce lytic EBV
gene transcription in latently infected cells with a methylated
viral genome. To determine whether the methylation status of
the latent EBV genome differentially affects the ability of wild-
type Z, Z(S186A), and Z(S186T) to disrupt viral latency, 293
cells latently infected with BZLF1-deleted EBV (293/EBV-
ZKO) (20) were treated with the DNA demethylating agent
5-aza-2-dc prior to transfection with a control vector or ex-
pression vectors for wild-type Z, Z(S186A), or Z(S186T). The
sensitivity of the Rp region to cutting by the methylation-
sensitive HpaII restriction enzyme was examined by Southern
blot analysis before and after 5-aza-2-dc treatment; the results
confirmed that the Rp region of the EBV genome was effi-
ciently demethylated following treatment (6). Cellular extracts
were analyzed 2 days posttransfection for the expression of Z,
R, BMRF1 (an early viral protein), or -actin by immunoblot-
ting.
As previously reported (6), prior demethylation of the viral
genome significantly reduced, but did not completely abolish,
the ability of wild-type Z to activate transcription of either the
immediate-early (IE) BRLF1 gene or the early BMRF1 gene
(Fig. 6A). In contrast, the Z(S186T) mutant, which binds only
to the methylated form of the Rp ZRE-2 motif, only induced
lytic EBV gene transcription from the methylated viral genome
(Fig. 6A). Furthermore, the defect in the Z(S186T) mutant was
limited to its inability to activate the Rp, since the defect in
activating BMRF1 transcription from the unmethylated viral
genome could be rescued by cotransfection with an R expres-
sion vector (Fig. 6B). The Z(S186A) mutant, as expected,
could not induce lytic gene transcription from either the meth-
ylated or demethylated viral genome (Fig. 7), although in both
cases this defect was rescued by cotransfection with the R
expression vector (Fig. 7 and data not shown). These results
suggest that the serine residue at position 186 in Z plays an
important role in inducing lytic viral infection from both the
unmethylated and methylated viral genomes.
Phosphorylation of the serine residue at position 186 is not
required for the ability of Z to bind preferentially to the meth-
ylated Rp ZRE-2. Serine residue 186 is phosphorylated by
protein kinase C (PKC) in vitro (4) and thus could potentially
be phosphorylated in vivo (as well as in reticulocyte extracts).
Previous results by another group showed that in vitro phos-
phorylation of Z protein by PKC decreased its binding to
unmethylated ZRE sites (4). To examine whether Z phosphor-
ylated at serine 186 behaves differently than the unphosphor-
ylated protein in regard to its binding to methylated versus
unmethylated ZRE motifs, we performed several different ex-
periments. First, we compared the binding of a bacterially
expressed and purified protein containing Z linked in frame to
GST (GST-Z) to the methylated versus unmethylated forms of
FIG. 3. Z(S186T) binds almost exclusively to the methylated form
of the Rp ZRE-2 site. Increasing amounts of methylated versus un-
methylated ZRE-2 cold competitor oligoprobe were used to compete
binding of Z(S186T) to a methylated 32P-labeled ZRE-2 probe. Z
binding complexes were quantitated, and the percent Z binding (rel-
ative to the amount in the absence of specific competitor DNA, set at
100%) is indicated. , present; , absent; retic, rabbit reticulocyte
lysate; NC, no competitor.
7342 BHENDE ET AL. J. VIROL.
ZRE-2. The GST-Z protein clearly bound more efficiently to
the methylated form of the ZRE-2 site (Fig. 8A). Since this
bacterially derived protein presumably cannot be phosphory-
lated, this result indicates that the unphosphorylated form of Z
binds more efficiently to the methylated versus unmethylated
form of the Rp ZRE-2 site.
Second, we constructed a Z mutant, Z(S186D), in which the
serine residue at position 186 was switched to an aspartic acid
residue to mimic the phosphorylated form of Z. Interestingly,
the in vitro-translated Z(S186D) mutant did not bind detect-
ably to either the AP-1 site in the BMRF1 promoter or the
methylated or unmethylated forms of the Rp ZRE-2 site
(Fig. 8B). Consistent with its inability to bind to DNA, the
Z(S186D) mutant was also unable to induce R and BMRF1
expression in 293/EBV-ZKO cells (Fig. 8C). This suggests that
phosphorylation of Z at position 186 is certainly not required
for its ability to bind preferentially to the methylated Rp ZRE-
2 site and may instead globally inhibit Z binding to multiple
different motifs.
FIG. 4. Comparison of wild-type Z, Z(S186A), and Z(S186T) bind-
ing in transfected DG75 cells extracts. (A) EMSA was performed using
either unmethylated or methylated (as indicated) 32P-labeled oligonucle-
otide probes containing ZRE-1, ZRE-2, or ZRE-3 motifs and whole-cell
extracts harvested from DG75 cells transfected with vector DNA or wild-
type Z (Wt Z), Z(S186A), or Z(S186T). The binding abilities of mu-
tant Z proteins to each probe were measured relative to wild-type Z,
which was set at 100% for each probe. (B) Immunoblot analysis of the
whole-cell extracts made from DG75 cells transfected with an empty
vector (Vector) or a plasmid expressing wild-type Z, Z(S186A), or Z
(S186T) was performed using a monoclonal antibody directed against
Z. (C) EMSA was performed using DG75 whole-cell extracts contain-
ing normalized levels of wild-type Z and Z(S186T) (as shown in the
immunoblot) and 32P-labeled oligonucleotide probe containing meth-
ylated ZRE-2. ND, nondetectable binding; , present; , absent.
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DSCUSSION
DNA methylation plays an important role in regulation of
both viral and cellular gene expression. Most models regarding
the effect of DNA methylation on gene transcription propose
that gene methylation leads to gene silencing either by pre-
venting the binding of transcription factors to promoters or by
imposing a restrictive chromatin state. Nevertheless, we re-
cently demonstrated that the EBV Z protein, which mediates
the switch between latent and lytic EBV infection, actually
requires its immediate downstream target promoter, Rp, to be
methylated to activate this promoter efficiently (6). We iden-
FIG. 5. Mutation of Z residue 186 affects its ability to activate
methylated Rp in CAT reporter gene assays. A vector containing the
CAT gene linked to the BRLF1 promoter (Rp-CAT), either methyl-
ated or mock-methylated in vitro, was transfected into DG75 cells
(A) or 293T cells (B) in combination with either empty vector (vector)
or vector expressing wild-type Z (Wt Z), Z(S186A), or Z(S186T), as
indicated. CAT activity was measured as the percentage of acetylation.
The methylation status of each promoter construct is indicated. ,
present; , absent.
FIG. 6. Changing Z residue 186 from serine to threonine affects the
ability of Z to induce lytic EBV infection in a methylation-dependent
manner. (A) 293/EBV-ZKO cells (20) were treated with 5-aza-2-dc or
not treated, as shown, prior to transfection with either empty vector
(Vector) or a vector expressing wild-type Z (Wt Z) or Z(S186T). The
methylation status of the EBV genome after the 5-aza-2-dc treatment
is indicated. Immunoblots were performed on cell extracts 2 days after
transfection with monoclonal antibody directed against Z, BMRF1 (an
early lytic EBV protein), R, or -actin, as indicated. (B) 293/EBV-ZKO
cells pretreated with 5-aza-2-dc were transfected with empty vector or
a vector expressing R, Z(S186T), or both R and Z(S186T). The meth-
ylation status of the EBV genome is indicated. Immunoblotting was
performed for Z, BMRF1, or -actin, as indicated. , present; , absent.
7344 BHENDE ET AL. J. VIROL.
tified two ZRE sites in Rp (ZRE-2 and ZRE-3) that can be
methylated through a CpG motif and showed that Z binding to
these atypical ZRE sites, as well as Z activation of Rp, was
surprisingly enhanced by methylation. Most importantly, Z
induced lytic EBV gene transcription in latently infected cells
more efficiently when the viral genome was methylated than
when it was demethylated. In contrast, the ability of the R IE
protein to disrupt viral latency in 293 cells latently infected
with BRLF1-deleted EBV (293/EBV-RKO) cells was en-
hanced by prior demethylation of the viral genome (6).
In this study, we have examined the effect of serine residue
186 in the Z DNA-binding domain on the ability of Z to
efficiently bind to and activate the methylated versus unmeth-
ylated forms of Rp. As the crystal structure of a Fos-Jun het-
erodimer binding to a consensus AP-1 site suggested that Z
residue 186 would directly contact the methylated cytosine in
the Rp ZRE-2 motif (TGAGCGA) (25), we hypothesized that
this residue might be important for mediating Z activation of
methylated Rp. Our results indicate that a Z mutant in which
residue 186 is switched from a serine to threonine, Z(S186T),
binds to the methylated form but not to the unmethylated form
of the Rp ZRE-2 site in vitro and induces lytic EBV transcrip-
tion from the methylated viral genome but not from the de-
methylated viral genome in vivo. The inability of this mutant to
activate early lytic EBV gene transcription from the demeth-
ylated viral genome was rescued by R, suggesting that the
Z(S186T) defect primarily reflects its inability to induce tran-
scription from unmethylated Rp. In contrast, the Z(S186A)
mutant, although able to bind efficiently to the consensus AP-1
site, could not bind efficiently to any of the three Rp ZRE sites
in either the methylated or unmethylated form. Consistent
with this binding defect, the Z(S186A) mutant could not acti-
vate transcription from either the methylated or demethylated
form of the EBV viral genome.
The previous description of the Z(S186T) mutant as being
close to wild-type Z in its ability to induce lytic EBV infection
from the intact viral genome in Raji cells (24) is not particu-
larly surprising given our finding here that Rp is highly meth-
ylated in Raji cells (as well as the other cell lines examined).
Another group recently examined the methylation state of the
BRLF1 and BZLF1 promoters in a series of nasopharyngeal
carcinomas (11). Similar to our results here, Rp was found to
be highly methylated in latently infected tumors. Whether the
Z(S186T) mutant would have a more obvious defect in situa-
tions such as primary lytic EBV infection in which the viral
genome does not become methylated is as yet unknown.
Serine and threonine are very similar polar amino acids
containing a hydroxyl group. This might explain the fact that
Z(S186T) retains the ability to bind to and activate methylated
Rp and induce lytic EBV infection from the methylated viral
genome. On the other hand, the replacement of serine 186
with alanine, a nonpolar amino acid, significantly decreases Z
binding to all three Rp ZRE sites, regardless of the ZRE site
methylation status, and abolishes the ability of Z to induce lytic
gene expression from the intact viral genome regardless of the
viral methylation state.
One surprising aspect of our results was the lack of corre-
lation between the ability of the Z(S186A) mutant to activate
the unmethylated Rp-CAT vector versus its ability to activate
BRLF1 transcription from the unmethylated viral genome. The
inability of this mutant to activate the BRLF1 transcription
from the intact viral genome (in either the methylated or
unmethylated state) is consistent with its inability to bind sig-
nificantly to any of the three Rp ZRE sites in vivo. The unre-
solved issue, however, is how this mutant activates the unmeth-
ylated Rp-CAT vector in reporter gene assays. It is possible
that very weak binding of this mutant is sufficient to activate
the unmethylated promoter in the context of naked DNA but
not in the chromatin context of the intact viral genome. Alter-
natively, we favor the hypothesis that Z(S186A) activates the
unmethylated Rp-CAT construct through an indirect mecha-
nism not requiring direct protein binding to the Rp ZRE sites.
Consistent with this, another Z mutant that is globally defec-
tive in DNA binding (due to an alteration of residues 178, 179,
and 180) was reported to activate certain promoters (including
the BZLF1 and BRLF1 promoters) through an indirect mech-
anism (22). However, this alternative mechanism for Z tran-
scriptional effects is clearly not sufficient to activate lytic gene
transcription in the context of the intact viral genome.
Phosphorylation is a common mechanism for regulating the
function of proteins, and Z can be phosphorylated in vitro at
serine 186 by PKC (4). We speculated that phosphorylation of
Z residue 186 in vivo (which could occur on either a serine or
threonine) may be required for Z binding to methylated Rp
ZRE sites, although PKC-mediated phosphorylation of GST-Z
was previously reported by another group to inhibit its binding
in vitro to unmethylated ZRE sites (4). However, our results
did not support this hypothesis. Bacterially expressed and pu-
rified GST-fused Z protein (GST-Z), which is not phosphory-
lated, also bound preferentially to the methylated form of the
Rp ZRE-2 motif. Furthermore, a mutant form of Z in which
serine 186 was replaced with aspartic acid to mimic a phos-
FIG. 7. The Z(S186A) mutant is defective for inducing lytic EBV
gene expression regardless of the methylation state of the EBV ge-
nome. 293/EBV-ZKO cells (untreated or pretreated with 5-aza-2-dc,
as indicated) were transfected with empty vector (vector) or a vector
expressing wild-type Z (Wt Z, 0.5 g in lane 2 and 1 g in lane 3),
Z(S186A), R, or both Z(S186A) and R, and immunoblots were per-
formed for Z, R, BMRF1, or -actin, as indicated. The methylation
status of the EBV genome is indicated. , present; , absent.
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FIG. 8. Phosphorylation of Z serine residue 186 is not required for Z binding to methylated Rp ZRE-2. (A) EMSA was performed using
bacterially expressed purified GST-Z and 32P-labeled oligonucleotide probes containing the AP-1 site in the BMRF1 promoter and either
unmethylated or methylated (as indicated) 32P-labeled oligonucleotide probes containing ZRE-2. (B) EMSA was performed using in vitro-
translated wild-type Z (Wt Z) and Z(S186D) (as shown) and 32P-labeled oligonucleotide probes containing the AP-1 site in the BMRF1 promoter
and either unmethylated or methylated (as indicated) 32P-labeled oligonucleotide probes containing ZRE-2. (C) 293/EBV-ZKO cells (20) were
transfected with either control vector (Vector) or a vector expressing wild-type Z (Wt Z) or Z(S186D). Immunoblots were performed on cell
extracts 2 days after transfection with monoclonal antibody directed against Z, R, BMRF1, or -actin, as indicated. , present; , absent; retic,
rabbit reticulocyte lysate.
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phorylated residue did not bind detectably to either the AP-1
site in the BMRF1 promoter or the unmethylated or methyl-
ated form of the Rp ZRE-2 site. Consistent with its DNA-
binding defect, Z(S186D) was also unable to induce R and
BMRF1 expression in 293/EBV-ZKO cells. Thus, phosphory-
lation of Z at position 186 is certainly not a prerequisite for its
ability to bind preferentially to the methylated form of Rp
ZRE-2 and may instead inhibit Z DNA binding globally. Fur-
thermore, the majority of evidence suggests that Z is not con-
stitutively phosphorylated at position 186 in vivo, nor is PKC
required for Z disruption of viral latency (17). As there is some
evidence suggesting that Z binds to DNA sites using more than
one protein conformation (17), another potential explanation
for the binding effects of the Z(S186A) and Z(S186T) muta-
tions is that different Z conformations are required for binding
to the methylated versus unmethylated forms of the Rp ZRE-2
site and that only wild-type Z can assume the different confor-
mations required to bind to both forms of this site.
Methylation of the EBV genome may protect the host cell by
shutting off transcription of potentially transforming latency
genes (in particular, LMP1) expressed in type II and III latency
and converting the virus to the most stringent, nontransform-
ing, form of latency, type I (42, 45). Nevertheless, EBV ge-
nome methylation also promotes persistence of EBV by inhib-
iting expression of viral latency proteins that are recognized by
cytotoxic T cells (42, 45). In addition, methylation of the EBV
genome presumably inhibits the well-known ability of unmeth-
ylated CpG motifs to activate Toll-like receptor 9 (3). Inter-
estingly, LMP1 was recently shown to activate expression of
cellular methyl transferases (53), suggesting that EBV actually
promotes its own genome methylation. Although methylation
may be beneficial to the virus in terms of promoting viral
latency and evading the host immune system, if EBV could not
efficiently convert back to the lytic form of infection from a
methylated viral genome under appropriate circumstances, it
would not have successfully infected the great majority of the
human population. The ability of the EBV lytic switch protein
Z to activate the methylated form of the IE BRLF1 promoter
likely contributes to the long-term success of this virus as both
a latent and lytic pathogen.
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